Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

expenses between periods were primarily due to planned increases in employee headcount and related costs, legal costs, and selected pre-launch spending for carfilzomib.

Onyx recorded $5.9 million of non-cash contingent consideration expense in the third quarter 2011 associated with changes in the fair value of the liability for contingent consideration recorded for the potential milestone payments under the Proteolix acquisition.

Interest ExpenseInterest expense of $5.1 million for the third quarter 2011 primarily relates to the 4.0% convertible senior notes due 2016 issued in August 2009 and includes non-cash imputed interest expense of $2.6 million as a result of the application of ASC 470-20.

Cash, Cash Equivalents and Marketable SecuritiesOn September 30, 2011, cash, cash equivalents, and current and non-current marketable securities were $529.7 million compared to $577.9 million at December 31, 2010. This excludes restricted cash of $31.9 million at December 31, 2010.  Subsequent to September 30, 2011, the Company received $160 million as part of the sale of Nexavar royalties in Japan, to Bayer.

Nine-Month ResultsNexavar net sales, as recorded by Bayer, were $731.5 million and $676.7 million for the nine months ended September 30, 2011 and 2010, respectively. Non-GAAP net loss for the nine months ended September 30, 2011 was $60.9 million, or $0.96 per diluted share, compared to non-GAAP net income of $56.6 million, or $0.90 per diluted share for the same period in 2010. A description of the non-GAAP calculations is provided below in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income (Loss)." For the nine months ended September 30, 2011, on a GAAP basis Onyx recorded a net loss of $140.6 million, or $2.22 per diluted share, compared with a net loss of $67.7 million, or $1.08 per diluted share, for the same period in 2010.

Management Conference Call TodayO
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 ... Society of Clinical Oncology    PharmaMar comunica ... SAR3007, resi noti dal dipartimento Ricerca e sviluppo ... miglioramento della sopravvivenza libera da progressione (PFS) dopo il ... con dacarbazina in pazienti con liposarcoma (LPS) o leiomiosarcoma ...
(Date:6/1/2015)... June 2, 2015 Amgen (NASDAQ: ... on a Phase 1b study to evaluate the ... oncolytic immunotherapy, in combination with Roche,s investigational anti-PDL1 ... with triple-negative breast cancer and colorectal cancer with ... investigational oncolytic immunotherapy designed to selectively replicate in ...
(Date:6/1/2015)... 1, 2015 Research ... the addition of the "Analysis of ... report to their offering.      ... in-depth analysis of the US Medical Image ... market dynamics, and trends across the US ...
Breaking Medicine Technology:PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 2PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 3PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 4PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 5PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7Analysis of the US Medical Image Displays Market 2015-2017 2
(Date:6/2/2015)... 02, 2015 Mercy Health (formerly Catholic ... and Kentucky – has devoted the seventh of its ... skin cancer prevention. One in five Americans will get ... Health’s YouTube channel, a Mercy Health expert addresses these ... main causes of skin cancer? ,     What are ...
(Date:6/2/2015)... The Radiosurgery Society® (RSS), a ... RSSearch® Patient Registry evaluating the treatment patterns and ... the treatment of centrally located primary non-small cell ... The study, published in the May, 2015, issue ... patients with 114 centrally located lung tumors who ...
(Date:6/2/2015)... 02, 2015 FDA approved Orlistat for ... patients after a satisfactory doctor consultation. The less potent, over-the-counter ... several years and has the longest track record as an ... enzyme that breaks down fats in foods, Orlistat treatment prevents ... intestinal system to be excreted through feces. , ...
(Date:6/2/2015)... June 02, 2015 Thermi, formerly ... company has successfully transitioned into its new company ... to the company’s continued rapid worldwide expansion and ... of over 25 Thermi employees, including those of ... teams. , “As one of the fastest growing ...
(Date:6/2/2015)... 2015 While the movie box office ... books, comic books themselves are stepping into a new ... plans to produce educational comics in multiple languages that ... Sustainable Development - an international effort to address humanity’s ... education, sustainable energy, inequality, climate change and more. , ...
Breaking Medicine News(10 mins):Health News:Video provides helpful information about skin cancer prevention 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 4Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3
... 2008: , The guidelines are developed through a ... in the field and a review committee of 21 ... for the first time both acute and chronic heart ... that patients with acute heart failure often develop chronic ...
... Lingering depression is a serious and common ... well with existing treatments. Because individuals with ... deficiency, an antioxidant that protects cells from toxins, ... in the September 15th issue of Biological ...
... study to date examining the impact of positron emission ... suspected recurrent colorectal cancer, researchers found that treatment plans ... to an article in the September issue of ... was conducted at four sites throughout Australia and comprised ...
... and Drug Administration Modernization Act (FDAMA, 1997), designed to ... in more than 130 label changes since its inception ... Children,s Hospital. , Their analysis appears in the September ... subsequent renewal of this legislation, pharmaceutical companies were given ...
... CHICAGO, Sept. 1 Dr. Charmaine Yoest,President and CEO ... response to news that the daughter of McCain running ... five children, I know this situation is not the ... we react to life,s,challenges is the true testament to ...
... and have higher heart rates, researchers say , , MONDAY, ... games, and playing active versions of these games may ... Kong researchers report. , In fact, children playing ... four times as many calories a minute than children ...
Cached Medicine News:Health News:New study finds that add-on therapy improves depressive symptoms in bipolar disorder 2Health News:PET scans lead to treatment changes in majority of colorectal cancer patients 2Health News:Post-marketing studies finding adverse events in drugs used in children 2Health News:Post-marketing studies finding adverse events in drugs used in children 3Health News:Active Video Games Help Kids Exercise 2Health News:Active Video Games Help Kids Exercise 3
... is a plastic device that fits over a ... with a minimum amount of reagent. , ... gap between the coverplate and slide. The ... reagent is dispensed into the well. Its ...
The first instrumentation to automate and efficiently manage the slide labeling process. Proven technology automatically feeds, prints and collates slides sequentially. Extensive data customization, ...
... wall-mounted organizer with a complete set of micro ... The Micro Nest makes it easier for technicians ... task. These small instrument cleaning brushes from ISI ... as cannulas. ISI Micro Brushes are available in ...
... "SSK" stands for Stainless Steel ... convenient instrument rust and stain remover for ... extend the life of your instruments by ... deposits. The result: pivot points, box joints ...
Medicine Products: